Collectively, these results suggest that PLAU may be an independent biomarker for predicting the outcomes of HNSCC patients and potentially contribute to tumour immunosuppression either in concert with or via TNFRSF12A [39]. This evidence concerns the gene TNFRSF12A and neoplasm.